TSLA came down a bit but not enough for me to want to add more.
Airlines, same thing.
BKD down like 6% today, what gives. Seems random.
Have you read through the clinicals on LXRX?
Make sure to read them thoroughly. Press releases in pharma are so misleading.
Did it hit the initially planned primary and secondary endpoints? Are they meaningful endpoints? Did every group hit them? Were the results very decisive since Phase III always tends to be worse than Phase II. Did they unreasonable pre-screen patients or post screen the groups? What were the feedback of the KOLs associated with the trial?
Then finally how is the market pricing it? Is it expecting a billion dollars of sales for the current value to make sense? Sometimes a stock has a decent sounding pipeline so all semblance of an achieve able valuation goes out the window.
Insurance and reimbursement is always a toss up. Even projecting these things professionally I may as well throw darts at a board to figure out how it will shake out.
None of LXRX's products were in new treatment areas, in fact they were very competitive treatment areas such as Diabetes and RA. I didn't see if they had any novel MOAs compared to what is out there already since at least that has a chance of responding to previously non responsive patients.
As for Gilead curing patients, that is actually good for business. If you can get away with 80% of the revenue for a cure up front it's not only better from a time value of money perspective but from a market share perspective too. Someone will inevitably make a better chronic treatment in a few years and your revenue stream will dry up. Or even if they don't you patent will expire and your drug will go generic. Yet the pharma makes more money from treatment than cures line just will not die...
Sure, but most aren't novocure.
I think you're missing that it's a bigger cash cow.
Gilead can get away with charging 80% of the lifetime chronic cost, probably down to 50% weighted after rebates and everything. That is a hell of a lot of money up front. It also means less people will assault the market in the future. On top of that no one gets the chronic treatment cost forever. Other companies come out with new and better drugs. Patents expire.
If a cure is worth 50% of the lifetime chronic cost and you have 100% of the market, that is a lot more valuable than being the leading chronic treatment for 3-5 years (not to mention there is a slow switch over to new chronic treatments, if old patients will even switch).